Pros and cons of therapeutic drug monitoring of antiretroviral agents

Current Opinion in Infectious Diseases

Volumn 15, Issue 1, 2002, Pages 17-22

  Burger, David M ^a   Aarnoutse, Rob E ^a   Hugen, Patricia W H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ANTIVIRAL ACTIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT CARE; PATIENT COMPLIANCE; REVIEW;

EID: 0036155095     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200202000-00004     Document Type: Review

References (20)

1. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors
2. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study
3. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
4. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals
5. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationship in HIV-infected persons
6. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
7. The relationship between ritonavir plasma levels and side-effects: Implications for therapeutic drug monitoring
8. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients
9. A retrospective, cohort-based survey of patients using twice daily indinavir plus ritonavir combinations: Pharmacokinetics, safety and efficacy
10. The role of therapeutic drug monitoring in treatment of HIV infection
11. Interactions among drugs for HIV and opportunistic infections
12. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
13. Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: Relationship to virologic response
14. Patient-reported nonadherence to HAART is related to protease inhibitor levels
15. An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy
16. Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children
17. Indinavir concentrations and St John's wort
18. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
19. Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens
20. Indinavir plasma protein binding in HIV-1 infected adults